The treatment of opioid-induced constipation (OIC) relies on various prescription medications, including several agents approved for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) and used off-label. The market faces challenges with low drug treatment rates, as many patients opt for over-the-counter (OTC) therapies. As a result, recently approved drugs like Motegrity and Zelnorm struggle to gain market share, while established treatments like Linzess and Movantik maintain use in both newly diagnosed and recently treated patients. Low persistency and compliance rates underscore the need to secure early use in this market.
Questions answered
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Allergan, Ironwood, Synergy Pharma, Takeda, Mallinckrodt, Alfasigma, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals, Endo Pharma
Key drugs: Motegrity, Linzess, Trulance, Ibsrela, Relistor, Symproic, Movantik, Amitiza, lubiprostone generic, naloxone, stimulant laxatives, osmotic laxatives, dietary fiber supplements
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.